Marksans Pharma, a prominent player in the pharmaceutical industry, revealed its robust Q3 and nine-month FY24 results on February 14, 2024. The company showcased impressive growth, with a 22% year-on-year increase in revenue, driven by market share expansion and new product launches across key markets. Additionally, Marksans Pharma bolstered its margin profile, achieving an EBITDA margin of 22.7% in Q3 through operating leverage and cost optimisation initiatives.
Net profit soared by 33.2% year-on-year to Rs 83 crore, accompanied by an EPS of Rs 1.843. The company attributed its stellar performance to strong growth in the UK, EU, and North American markets, coupled with improved volume growth in Australia, New Zealand, and other regions.
Marksans Pharma outlined strategic initiatives aimed at further growth and market penetration. Notably, the company is investing in infrastructure expansion, particularly from the newly acquired Teva plant in Goa, to capitalize on incremental opportunities in diverse geographies. Moreover, Marksans Pharma is focusing on backward integration by filing Drug Master Files (DMFs) for key products, a move intended to control the supply chain and reduce dependency on external suppliers.
The company plans to file 34 new products in the UK market within the next two years, emphasizing niche and high-value products with promising bottom lines.
During the conference call, Marksans Pharma addressed queries from analysts and investors, providing valuable insights into its operations and growth trajectory. The company remains optimistic about its growth prospects in the UK and US markets, expecting healthy double-digit growth driven by product portfolio expansion and market penetration strategies.
Furthermore, Marksans Pharma is committed to strengthening its Over-The-Counter (OTC) business segment and pursuing calibrated inorganic growth opportunities to expand its presence, particularly in growing markets and the EU.
The company reported a substantial increase in revenue, indicating the successful reception of its products and services in the market. Improved volume growth, strategic initiatives, and favorable market conditions contributed to this revenue surge.
Additionally, institutional interest in Marksans Pharma has surged, with FII holdings increasing to 15.55% and DII holdings to 4.76% for the quarter ending Dec-23, reflecting growing confidence among investors.
Marksans Pharma’s Q3 performance and strategic initiatives underscore its resilience and potential for sustained growth in the pharmaceutical landscape. With a strong focus on innovation, market expansion, and operational excellence, the company is poised to capitalize on emerging opportunities and deliver value to its stakeholders.
As it continues to navigate evolving market dynamics and pursue strategic objectives, Marksans Pharma remains a compelling player in the pharmaceutical industry.
Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. The information is based on various secondary sources on the internet and is subject to change. Please consult with a financial expert before making investment decisions.
Published on: Feb 20, 2024, 5:09 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
